Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35435 clinical trials
Featured trial
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)

up to a minimum of 48 weeks and a maximum of 144 weeks. Certain medications for PD will be allowed at enrollment for a subset of participants. The majority of clinic visits will be

hoehn and yahr scale
movement disorder
  • 9 views
  • 17 Nov, 2022
  • 6 locations
Featured trial
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

daily. It has been well tolerated in earlier studies and may be a convenient option for Alzheimer’s patients and their families. To learn more about the clinical research study and to see if you may

mild dementia
mini-mental state examination
apolipoprotein e
dementia
  • 76 views
  • 20 Sep, 2022
  • 79 locations
Featured trial
Study to evaluate HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

(administered once daily (QD) or twice daily (BID)), or a placebo regimen for 52 weeks.Participants who complete all study visits may be eligible to enter a 52-week extension study where

rheumatism
raynaud's phenomenon
diffuse cutaneous systemic sclerosis
raynaud's syndrome
MRSS
  • 16 views
  • 22 Oct, 2022
  • 85 locations
Featured trial
Preventing Alzheimer's With Cognitive Training (PACT)

years. The primary contribution of the proposed research will be the determination of whether this cognitive training technique successfully delays the onset of clinically defined MCI or dementia across

mild cognitive impairment
Accepts healthy volunteers
cognitive stimulation
cognitive impairment
dementia
  • 1 views
  • 28 Oct, 2022
  • 5 locations
Featured trial
Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors (CARMEN-LC03)  

Primary Objectives: Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cutoff date for each given analysis (progression free

  • 132 views
  • 17 Nov, 2022
  • 5 locations
Featured trial
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.

  • 6 views
  • 25 Oct, 2022
  • 153 locations
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

  • 13 views
  • 25 Oct, 2022
  • 139 locations
Featured trial
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients (EVEREST)

Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives To evaluate the efficacy of dupilumab in improving CRSwNP symptoms at Week 24 compared to omalizumab To evaluate the efficacy of dupilumab in improving lung function at …

  • 25 views
  • 18 Nov, 2022
  • 72 locations
Featured trial
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule.  With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will

FGFR1
myeloid neoplasm
lymphoid malignancy
  • 182 views
  • 10 May, 2022
  • 35 locations
Featured trial
  • 24 views
  • 08 Feb, 2022
  • 20 locations